Yes. In a 7 Tesla resting-state fMRI crossover study in healthy volunteers, both 2C-B and psilocybin reduced within-network coherence (notably in visual systems and parts of the default mode network) while increasing cross-network and subcortical to cortical connectivity. Both also increased the complexity of spontaneous brain signals.
They were not identical, though. Psilocybin showed broader between-network changes, while 2C-B showed relatively stronger transmodal increases, including links between default mode and frontoparietal control regions. Participants retrospectively reported more intense and dysphoric experiences with psilocybin than with 2C-B, despite similar momentary intensity during scanning.
Spatial patterns of change aligned with 5-HT2A receptor density for both drugs, and differences also related to 5-HT1A and dopamine transporter maps, suggesting shared mechanisms with compound-specific fingerprints. The sample was small and the work was not a treatment study. For details, see the Molecular Psychiatry report published in 2026: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.
In short, they alter brain networks in similar ways but with distinct spatial profiles.